Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vtv Theraptcs Cl A (VTVT)

Vtv Theraptcs Cl A (VTVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,114
  • Shares Outstanding, K 3,010
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,250 K
  • 60-Month Beta 0.65
  • Price/Sales 61.10
  • Price/Cash Flow N/A
  • Price/Book 2.55
Trade VTVT with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.31 +44.14%
on 06/26/24
24.90 -5.58%
on 07/15/24
+4.68 (+24.85%)
since 06/21/24
3-Month
16.25 +44.68%
on 06/07/24
29.19 -19.46%
on 04/30/24
-1.47 (-5.87%)
since 04/23/24
52-Week
7.38 +218.56%
on 01/26/24
31.20 -24.65%
on 08/10/23
-5.10 (-17.82%)
since 07/21/23

Most Recent Stories

More News
VTv Therapeutics: Q1 Earnings Snapshot

VTv Therapeutics: Q1 Earnings Snapshot

VTVT : 23.51 (+2.40%)
VTv Therapeutics: Q4 Earnings Snapshot

VTv Therapeutics: Q4 Earnings Snapshot

VTVT : 23.51 (+2.40%)
VTv Therapeutics: Q3 Earnings Snapshot

VTv Therapeutics: Q3 Earnings Snapshot

VTVT : 23.51 (+2.40%)
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 23.51 (+2.40%)
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 23.51 (+2.40%)
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 23.51 (+2.40%)
Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 23.51 (+2.40%)
VTv Therapeutics: Q2 Earnings Snapshot

VTv Therapeutics: Q2 Earnings Snapshot

VTVT : 23.51 (+2.40%)
Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 23.51 (+2.40%)
CANTEX PHARMACEUTICALS OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM GEORGETOWN UNIVERSITY FOR AZELIRAGON AS A POTENTIAL TREATMENT OF CANCER-RELATED COGNITIVE DECLINE

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 23.51 (+2.40%)

Business Summary

vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical...

See More

Key Turning Points

3rd Resistance Point 26.91
2nd Resistance Point 25.86
1st Resistance Point 24.69
Last Price 23.51
1st Support Level 22.47
2nd Support Level 21.42
3rd Support Level 20.25

See More

52-Week High 31.20
Last Price 23.51
Fibonacci 61.8% 22.10
Fibonacci 50% 19.29
Fibonacci 38.2% 16.48
52-Week Low 7.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar